8-K: Decoy Therapeutics Executes 1-for-12 Reverse Stock Split

Decoy Therapeutics Inc. announced a 1-for-12 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.

Summary

• Decoy Therapeutics Inc. (DCOY) will effect a 1-for-12 reverse stock split of its common stock.
• The reverse stock split will become effective at 5:00 p.m. Eastern Time on March 6, 2026.
• Common Stock is expected to begin trading on a split-adjusted basis on Nasdaq when the market opens on March 9, 2026.
• The primary purpose of the reverse stock split is to enable the company to comply with The Nasdaq Capital Market's $1.00 minimum closing bid price requirement for continued listing.
• Every 12 shares of the company's issued and outstanding common stock will automatically be combined, converted, and changed into one share of common stock.
• The number of issued and outstanding shares will be reduced from approximately 6.38 million to approximately 532,000.
• The number of authorized shares (100 million common, 10 million preferred) and the par value per share ($0.0001 for both common and preferred) will remain unchanged.
• Any fractional share created as a result of the split will be rounded down, and stockholders will receive cash equal to the market value of the fractional share, determined by the closing sales price on Nasdaq on March 6, 2026.
• Outstanding stock options, restricted stock units, and warrants to purchase common stock will be proportionately adjusted.
• The new CUSIP number for the Common Stock following the Reverse Stock Split will be 79400X602.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a necessary but reactive measure to maintain listing compliance, which often indicates underlying stock performance issues. While it addresses a technical requirement, it doesn't inherently improve the company's fundamental value or prospects, though it prevents a more severe outcome (delisting).

Positives

• The reverse stock split is a necessary action to regain compliance with Nasdaq's continued listing requirements, preventing potential delisting and maintaining market access.

Negatives

• The necessity of a reverse stock split typically indicates a sustained low stock price, reflecting poor market performance or investor sentiment.
• While not directly impacting ownership percentage (except for fractional shares), reverse splits can sometimes be perceived negatively by investors.

Risks

• Risk that the Company will not obtain sufficient financing to execute on its business plans.
• Risks related to Decoy's products and development plans, including unanticipated issues with any Investigational New Drug (IND) application process.
• Risks related to the potential of the IMP3ACT platform.
• Actual results could differ materially from forward-looking statements due to various factors.

Future Outlook

The company aims to regain compliance with Nasdaq's minimum bid price requirement, which is crucial for its continued listing. Forward-looking statements also generally refer to the expected achievement of milestones for its lead asset and future prospects, but these are not specifically detailed in relation to the reverse split.

Management Comments

• Decoy Therapeutics is a preclinical-stage biopharmaceutical company that is engineering the next generation of peptide conjugate therapeutics.
• Decoy Therapeutics is a preclinical-stage biotechnology company that is leveraging ML and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs.
• The company's initial pipeline is focused on respiratory viruses and GI cancers.

Industry Context

StockSavvy.ai notes that reverse stock splits are a common strategy for companies, particularly in the biotechnology sector, to maintain listing compliance on major exchanges like Nasdaq when their stock price falls below minimum requirements. This action, while addressing a technical listing issue, often signals underlying challenges in market valuation or investor confidence, which is not uncommon for preclinical-stage biopharmaceutical companies facing long development timelines and high capital needs.

Comparison to Industry Standards

• Reverse stock splits are a standard corporate action for companies facing delisting from exchanges like Nasdaq due to low share prices. For example, other biotech companies such as Sorrento Therapeutics, Inc. or Aeterna Zentaris Inc. have undertaken similar actions to maintain listing status.
• The 1-for-12 ratio is within the typical range (often 1-for-2 to 1-for-20) seen in such compliance-driven splits across various industries.
• The proportionate adjustment of outstanding options, restricted stock units, and warrants is also standard practice to ensure equity incentive plans remain consistent post-split.

Corporate Governance

Stakeholder Impact

• Shareholders: Will see their number of shares reduced by a factor of 12, but their ownership percentage (excluding fractional shares) will remain the same. Those with fractional shares will receive cash. The action aims to protect their investment by maintaining Nasdaq listing.
• Employees (with equity incentives): Stock options, restricted stock units, and warrants will be proportionately adjusted to reflect the split, maintaining their intrinsic value.
• Investors: The action addresses a technical listing requirement, potentially improving liquidity and institutional investor interest by raising the per-share price. However, it also highlights past poor stock performance.

Next Steps

• Common Stock to begin trading on a split-adjusted basis on Nasdaq on March 9, 2026.
• Equiniti Trust Company, LLC will provide instructions to stockholders with physical certificates for exchanging them for post-split shares.
• Continued efforts to obtain sufficient financing to execute business plans.
• Ongoing product development, including potential IND application processes for its pipeline focused on respiratory viruses and GI cancers.

Key Dates

Recommendation

While the reverse stock split addresses a critical listing compliance issue, preventing potential delisting, it does not fundamentally alter the company's business prospects or financial health. The need for such an action often signals underlying challenges in market valuation. Investors should hold to observe if the company can leverage its continued listing to advance its preclinical pipeline and secure further financing, as the long-term value depends on clinical development success rather than this corporate action.

Keywords

Biotechnology, Reverse Stock Split, Nasdaq Compliance, DCOY, Biopharmaceutical, Peptide Conjugate, SEC Filing, Corporate Action, Stock Market, Delisting Risk